Your browser doesn't support javascript.
loading
The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era.
Kockerols, Camille C B; Geelen, Inge; Levin, Mark-David; Janssen, Jeroen J W M; Dinmohamed, Avinash G; Hoogendoorn, Mels; Cornelissen, Jan J; Westerweel, Peter E.
Affiliation
  • Kockerols CCB; Department of Internal Medicine, Hematology, Albert Schweitzer Hospital, Dordrecht. c.c.b.kockerols@asz.nl.
  • Geelen I; Department of Hematology, Erasmus University Medical Center, Rotterdam.
  • Levin MD; Department of Internal Medicine, Hematology, Albert Schweitzer Hospital, Dordrecht.
  • Janssen JJWM; Department of Hematology, Amsterdam University Medical Center, location VU Medical Center, Amsterdam.
  • Dinmohamed AG; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands; Department of Public Health, Erasmus University Medical Center, Rotterdam.
  • Hoogendoorn M; Department of Hematology, Medical Center Leeuwarden, Leeuwarden.
  • Cornelissen JJ; Department of Hematology, Erasmus University Medical Center, Rotterdam.
  • Westerweel PE; Department of Internal Medicine, Hematology, Albert Schweitzer Hospital, Dordrecht.
Haematologica ; 107(8): 1940-1943, 2022 08 01.
Article in En | MEDLINE | ID: mdl-35354254
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Leukemia, Myeloid Limits: Humans Language: En Journal: Haematologica Year: 2022 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Leukemia, Myeloid Limits: Humans Language: En Journal: Haematologica Year: 2022 Document type: Article